PARP1 and neoplasm: Anyhow, we believe a lot of the positive impact that might result from the introduction of the BRCA1/2 tumor testing, particularly because more patients should benefit from anti-PARP-1 targeted therapies or other similar new drugs coming soon [9, 10].